Press Releases Year All2024202320222021202020192018201720162015 Jun 25, 2024 Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease Jun 12, 2024 Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing May 30, 2024 Wave Life Sciences to Present at 2024 Jefferies Global Healthcare Conference May 09, 2024 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer May 07, 2024 Wave Life Sciences to Present at 2024 RBC Capital Markets Global Healthcare Conference May 02, 2024 Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024 Apr 30, 2024 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD) Apr 23, 2024 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing Mar 27, 2024 Wave Life Sciences to Present at Upcoming Investor Conferences
Jun 25, 2024 Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Jun 12, 2024 Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
May 09, 2024 Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
Apr 30, 2024 Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency (AATD)
Apr 23, 2024 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing